BNP (B-type Natriuretic Peptide) vs Thymosin Alpha-1

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

BNP (B-type Natriuretic Peptide)

BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.

Full details →

Thymosin Alpha-1

Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.

Full details →

Side-by-Side Comparison

Aspect	BNP (B-type Natriuretic Peptide)	Thymosin Alpha-1
Dose Range	25 mcg–100 mcg	1.6 mg–3.2 mg
Frequency	1x daily	Less than daily
Cycle Length	1–4 weeks	4–12 weeks
Route	subcutaneous	subcutaneous
Mechanism	Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress.	Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes.
Typical Dosage	Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure.	Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary.
Administration	Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically.	Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols.
Side Effects	Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients.	Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue.
Best For	Recovery & Healing	Recovery & Healing